The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).
 
Michael Geissler
Consulting or Advisory Role - Amgen; Amgen; Bayer Health; Bayer Health; Celgene; Celgene; GlaxoSmithKline; GlaxoSmithKline; Ipsen; Ipsen; Lilly; Lilly; Merck Serono; Merck Serono; MSD; MSD
Research Funding - Amgen; Amgen
 
Jorge Riera-Knorrenschild
No Relationships to Disclose
 
Uwe Marc Martens
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; MSD Oncology; Roche
Travel, Accommodations, Expenses - Amgen
 
Swantje Held
No Relationships to Disclose
 
Jobst Greeve
No Relationships to Disclose
 
Axel Florschütz
No Relationships to Disclose
 
Thomas Jens Ettrich
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck Serono; Merck Serono; Novartis; Novartis; Novartis; Pfizer; Sanofi; Sanofi; Sirtex Medical
Research Funding - Baxalta/Shire
Travel, Accommodations, Expenses - Ipsen; Ipsen
 
Stephan Kanzler
No Relationships to Disclose
 
Andrea Tannapfel
No Relationships to Disclose
 
Volker Heinemann
Honoraria - Amgen; Baxalta; Boehringer Ingelheim; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Baxalta; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Halozyme; Merck; MSD; Roche; Sanofi; SERVIER; Sirtex Medical
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Merck (Inst); Roche (Inst); Shire (Inst); Sirtex Medical (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Roche; SERVIER; Shire; Sirtex Medical
 
Anke C. Reinacher-Schick
Honoraria - Amgen; Baxalta; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD; Pfizer; Roche; Sanofi/Aventis; SERVIER; Shire
Consulting or Advisory Role - Amgen; Baxalta; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD; Pfizer; Roche; Sanofi/Aventis; SERVIER
Research Funding - Celgene; Ipsen; Roche; Sanofi/Aventis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen
 
Thomas Seufferlein
No Relationships to Disclose
 
Swen Wessendorf
No Relationships to Disclose
 
Dominik Paul Modest
Honoraria - Amgen; Bristol-Myers Squibb; Merck Serono; Pfizer; Roche; SERVIER; Sirtex Medical
Consulting or Advisory Role - Amgen; Bayer; Merck Serono
Research Funding - Amgen (Inst); Merck Serono (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Merck Serono; SERVIER